|Abstract:||The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.|
|Inventor(s):||Chu; Hui-May (Natick, MA), Ette; Ene (Framingham, MA), McNair; Lindsay (Allston, MA), Alam; John (Cambridge, MA)|
|Assignee:||Vertex Pharmaceuticals Incorporated (Cambridge, MA)|
1. A therapeutic regimen comprising administering for a period of at least 14 days: a. VX-950, or a pharmaceutically acceptable salt thereof, three times per day in an amount of about
750 mg; b. pegylated interferon in an amount of about 180 .mu.g/wk; and c. ribavirin.
2. The regimen of claim 1, wherein the amount of VX-950 is administered every 8 hours.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.